New drug cocktail shows promise in taming tough cancers
NCT ID NCT04705818
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tested a combination of two drugs, durvalumab (an immunotherapy) and tazemetostat (an epigenetic therapy), in 164 adults with advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The goal was to see if the combo could shrink or stabilize tumors. Since patients may need ongoing treatment, this is about disease control, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Brest
Brest, 29200, France
-
CHU Poitiers
Poitiers, 86000, France
-
Institut Bergonie
Bordeaux, 33076, France
Conditions
Explore the condition pages connected to this study.